1. Home
  2. SST vs NOTV Comparison

SST vs NOTV Comparison

Compare SST & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

N/A

Current Price

$2.08

Market Cap

27.4M

ML Signal

N/A

Logo Inotiv Inc.

NOTV

Inotiv Inc.

N/A

Current Price

$0.40

Market Cap

12.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SST
NOTV
Founded
2013
1974
Country
United States
United States
Employees
300
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
12.7M
IPO Year
N/A
1997

Fundamental Metrics

Financial Performance
Metric
SST
NOTV
Price
$2.08
$0.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$10.00
$1.50
AVG Volume (30 Days)
8.5K
564.7K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
49.64
EPS
N/A
N/A
Revenue
N/A
$547,656,000.00
Revenue This Year
N/A
$5.28
Revenue Next Year
N/A
$5.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
511.19
52 Week Low
$0.29
$0.25
52 Week High
$11.30
$3.35

Technical Indicators

Market Signals
Indicator
SST
NOTV
Relative Strength Index (RSI) 21.30 51.64
Support Level $0.34 $0.26
Resistance Level $4.61 $0.65
Average True Range (ATR) 0.28 0.05
MACD -0.07 0.03
Stochastic Oscillator 9.14 63.79

Price Performance

Historical Comparison
SST
NOTV

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: